Here's how much Valeant short sellers have been killing it ever since Bill Ackman got in the stock (VRX)
Reuters
A quick note on Valeant Pharmaceutical short sellers from Wall Street analytics firm, S3 Partners – something to give a little context to hedge fund billionaire Bill Ackman's exit from the company.
"VRX short sellers were profitable every year after Bill Ackman’s entry into the stock, eventually earning a 343.45% return on their average short position of $801 million," the firm said in a note to clients.
You'll recall that Bill Ackman started buying Valeant stock after... Читать дальше...